- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03253757
PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation
HIV pre-exposure prophylaxis (PrEP) is the use of anti-HIV medicines by HIV negative people in order to prevent them from becoming HIV positive if exposed to HIV.
Currently, the combination drug containing tenofovir and emtricitabine is licensed in Europe for use as HIV PrEP. We know from previous studies worldwide that this combination drug is very good at reducing the risk of HIV infection and several countries have implemented PrEP programmes to provide PrEP to individuals at high risk of HIV.
However, it is difficult to effectively plan for a national PrEP programme in England without knowing how many people will need PrEP, how many will want to take PrEP, and how long they will stay on PrEP.
In order to find this out, the PrEP Impact Trial will make PrEP available to at least 10,000 people over three years. HIV negative men and women attending sexual health clinics in England will have their risk of HIV assessed by their care team and be offered PrEP if they meet the eligibility criteria. Through the trial we will be able to measure how many attendees at sexual health clinics meet eligibility criteria for PrEP, how many of these take up the offer of PrEP and how long they remain on PrEP for.
There will not be any additional tests other than those recommended for the safe delivery of PrEP. These include tests for sexually transmitted infections (STIs) and HIV as well as urine and blood tests to monitor kidney function. Information about attendances and test results will be anonymously collected through the existing data reporting system that sexual health clinics currently use to report to Public Health England.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Hannah Reaney
- Phone Number: 07887476175
- Email: impact@ststcr.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The participant populations for this trial will be men and women attending GUM clinics who belong to one of three populations recognised to be at high risk for HIV, namely:
A. Men (cisgender and transgender) and transgender women who:
- Have sex with men
- Have had an HIV negative test during an earlier episode of care in the preceding year
- Report condomless intercourse in the previous 3 months
- Affirm their likelihood of having condomless intercourse in the next 3 months
B. HIV negative partners of an HIV positive person when:
- The HIV positive partner is not known to be virally suppressed (<200 copies/ml for 6 months or more)
- Condomless intercourse is anticipated before treatment of the HIV positive partner takes effect
C.HIV negative persons who:
1. Are clinically assessed and considered to be at similar high risk of HIV acquisition as those with a serodiscordant partner who is not known to be virally suppressed
Description
Inclusion Criteria:
The participant populations for this trial will be men and women attending GUM clinics who belong to one of three populations recognised to be at high risk for HIV, namely:
A. Men (cisgender and transgender) and transgender women who:
- Have sex with men
- Have had an HIV negative test during an earlier episode of care in the preceding year
- Report condomless intercourse in the previous 3 months
- Affirm their likelihood of having condomless intercourse in the next 3 months
B. HIV negative partners of an HIV positive person when:
- The HIV positive partner is not known to be virally suppressed (<200 copies/ml for 6 months or more)
- Condomless intercourse is anticipated before treatment of the HIV positive partner takes effect
C.HIV negative persons who:
1. Are clinically assessed and considered to be at similar high risk of HIV acquisition as those with a serodiscordant partner who is not known to be virally suppressed
Participants will therefore be considered eligible for trial enrolment if they fulfil all the following individual eligibility criteria:
- Belongs to one of the three at high HIV risk populations described above
- Aged 16 years or over (no upper limit)
- Considered to be HIV negative on the day of enrolment
- Willing and able to provide informed consent
- Willing to adhere to the recommended PrEP regimen
- Willing to re-attend the trial clinic at appropriate intervals for risk assessment
Exclusion Criteria:
- An acute viral illness that could be due to HIV seroconversion
- Any contraindication to Tenofovir Disoproxil (TD)/ Emtricitabine (FTC)-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PrEP Eligibility
Time Frame: 3 years
|
The proportion of GUM clinic attendees meeting the eligibility criteria for PrEP
|
3 years
|
PrEP Eligibility (duration)
Time Frame: 3 years
|
The duration for which GUM clinic attendees are eligible for PreP
|
3 years
|
PrEP Uptake
Time Frame: 3 years
|
The proportion of PrEP eligible GUM clinic attendees prescribed PrEP
|
3 years
|
PrEP Uptake (duration)
Time Frame: 3 years
|
The duration for which eligible GUM clinic attendees use PrEP
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HIV
Time Frame: 3 years
|
HIV diagnoses reported by sites and identified through the national surveillance dataset
|
3 years
|
STIs
Time Frame: 3 years
|
STI diagnoses (gonorrhoea, chlamydia, syphilis and hepatitis C) reported in the national surveillance dataset
|
3 years
|
Adverse Events
Time Frame: 3 years
|
|
3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SSCR104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on This study is non-interventional.
-
Korea Otsuka Pharmaceutical Co., Ltd.CompletedCerebral Infarction | Ischemic SymptomsKorea, Republic of
-
University Hospital of CologneClinic for Internal Medicine I, University Hospital Cologne, Germany; Institute... and other collaboratorsUnknownCOVID-19 | SARS-CoV-2Germany
-
Sanguine BiosciencesRecruiting
-
Amicus TherapeuticsEngage Health Inc.RecruitingFabry DiseaseUnited States
-
Hull University Teaching Hospitals NHS TrustUniversity of YorkRecruiting
-
University Hospital HeidelbergCompletedEmergencies | COVID-19 PandemicGermany
-
University of MalayaMichael J. Fox Foundation for Parkinson's Research; University of Dundee; Nextcea... and other collaboratorsUnknown
-
International Institute of Behavioral MedicinesRecruiting
-
University of PlymouthNot yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
KK Women's and Children's HospitalUniversity of PlymouthActive, not recruitingCritical Illness | Pediatric ALL | Post Intensive Care Unit SyndromeSingapore